Tag Archives: IPOs

Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq

COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies. On Friday, three firms added their names to the list of life science companies preparing to join the public markets. Gene therapy company Generation […]

Life Science a VC Bright Spot in Q1, But Startups May Soon Struggle

Even as the novel coronavirus has derailed daily life and business operations, the life sciences sector continues to see companies make public debuts and ink both financing and partnership deals. In venture capital, US deal activity in the first quarter tallied 2,300 financings totaling $34.2 billion, according to the latest report by the National Venture […]

Posted in National, National blog main, National top stories | Tagged acquisitions, Biotech, coronavirus, COVID-19, deals, investing, Investor, IPOs, Life Sciences, National Venture Capital Association, PitchBook, startups, VC, Venture Capital | Comments Off

Zentalis Leads a Trio of Biotechs Charting a Course for Wall Street

Cell therapies and antibody drugs grab much of the attention and investment in cancer drug development but the scientists at Zentalis Pharmaceuticals contend that there’s a place for small molecules too. Now the biotech is preparing for an initial public stock offering to advance its pipeline, which includes a lead candidate in testing in combination […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, New York, New York blog main, New York top stories | Tagged Acute Lymphoblastic Leukemia, Adenoid Cystic Carcinoma, AstraZeneca, Ayala Pharmaceuticals, B-cell lymphoma, Biotech, Biotech IPOs, Breast Cancer, Bridge Venture Partners, Bristol-myers Squibb, Cancer Drugs, chronic rhinosinusitis, clinical trials, Desmoid tumors, Drug Delivery, FDA, fulvestrant, IPOs, Israel Biotech Fund, Life Sciences, Lyra Therapeutics, Matrix Capital Management, mometasone furorate, Non-Small Cell Lung Cancer, Novartis, palbociclib, Perceptive Advisors, Pfizer, Recurium Equity, selective estrogen receptor degraders, Viking Global Investors, Zentalis Pharmaceuticals | Comments Off

Vir Bio Plans IPO to Fund Clinical Trials of Infectious Disease Drugs

Vir Biotechnology assembled its pipeline of infectious disease compounds through deal-making with other drug developers, along with financial support from blue-chip venture capital firms and the non-profit Bill & Melinda Gates Foundation. Now the biotech is turning to the public markets for the cash to continue clinical tests of its most advanced drug candidates. San […]

Posted in Boston blog main, National blog main, San Francisco, San Francisco blog main, San Francisco top stories, Seattle blog main | Tagged Alnylam Pharmaceuticals, ARCH Venture Partners, Bill & Melinda Gates Foundation, Biogen, Biotech, Biotech IPOs, clinical trials, Exelixis, George Scangos, Hepatitis B, HIV, Humabs Biomed, Infectious Disease, influenza, IPOs, Life Sciences, Robert Nelsen, SoftBank Vision Fund, startups, Vir Biotechnology | Comments Off

After Drought, Digital Health’s Summer of IPOs Brings Validation

After a nearly three-year period in which not a single digital health company held an initial public stock offering, the dry spell has ended. In recent weeks, four healthcare software and technology businesses—Change Healthcare, Health Catalyst, Livongo Health, and Phreesia—held IPOs. Taken as a whole, these public market debuts were mostly successful, and could persuade […]

Posted in Boston blog main, Boston top stories, National, National blog main, National top stories, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories | Tagged Change Healthcare, chardan, chronic conditions, Digital Health, Flare Capital Partners, Health Catalyst, healthcare, Healthtech, initial public offering, initial public offerings, IPO, IPOs, Livongo, Megan Zweig, Michael Greeley, mobile devices, Nasdaq, NYSE, Peloton, Phreesia, Rock Health, Software, steven wardell, Stock Market, Tech, VC, Venture Capital, xperience | Comments Off

Livongo Upsizes IPO to $355M in Bid to Become Netflix of Health

Livongo Health, a digital health company developing devices and software to help patients manage treatment for diabetes and other chronic conditions, said it expects to net $355.2 million in an initial public offering. Mountain View, CA-based Livongo late Wednesday priced its offering of approximately 12.7 million shares of its common stock at $28 per share. […]

Posted in National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged chronic conditions, diabetes, Digital Health, Echo Health Ventures, FDA, General Catalyst, Glen Tullman, healthcare, Healthtech, IPO, IPOs, Kleiner Perkins Caufield & Byers, Livongo, Microsoft, Pepsi, PepsiCo, Software, startups, Target, Tech | Comments Off

Genmab, Mirum Pharma & Fulcrum Raise $653M in Wall Street Debuts

Initial public offerings took a brief summer break the week of Independence Day, but healthcare IPO activity resumed this week as three more companies joined the US public markets. Here’s a recap of the biotech companies that priced IPOs Wednesday evening. —Genmab is different from the other life science companies that joined the public markets […]

IPO to Watch: Digital Health Developer Livongo Plans to Go Public

Digital health businesses haven’t had trouble raising venture capital funds from investors—2018 was a record year with $8.1 billion in funding—but few of them have made the move to hold initial public offerings. Livongo Health, a digital health company developing devices and software to help patients manage chronic conditions, believes it is ready, announcing Friday […]

Posted in National blog main, New York blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged Allscripts, CrunchBase, Digital Health, Glen Tullman, healthcare, Healthtech, IPOs, Livongo, livongo for diabetes, livongo health, Nasdaq, Software, Tech | Comments Off

Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More

[Corrected 6/24/19, 12:08 p.m. See below.] Cancer remains one of the hottest areas for pharma deals and this week saw a big one: Pfizer’s proposed $11.4 billion buyout of Array Biopharma. The announcement comes less than a month after Boulder, CO-based Array announced positive data from a pivotal study of its combination drug in colorectal […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged AbbVie, adalimumab (Humira), Akero Therapeutics, alacabrutinib, Alex Azar, Armune BioScience, ArQule, Array Biopharma, AstraZeneca, Atreca, BeiGene, BioHaven Pharmaceuticals, Biotech, Biotech IPOs, BlueBird Bio, C. Difficile, cancer, CAR-T, Chemotherapy, clinical trials, Colorectal Cancer, Comet Therapeutics, David Esposito, deals, Dermavant Sciences, DNA, drug prices, entrectinib, Erik Harris, European Hematology Association, FDA, Gene Therapy, Gilead Sciences, GlaxoSmithKline, google, Hepatitis B, ibrutinib, InVitae, IPOs, iqvia, Jason Coloma, Jessica Sachs, Life Sciences, Loxo Oncology, Lymphoma, Mani Foroohar, MapKure, Martin Shkreli, Maze therapeutics, Merck, metabolic disorders, Microbiome, Mikael Dolsten, Nurix Therapeutics, olaparib (Lynparza), ONL Therapeutics, pembrolizumab, Personalis, Pfizer, Pharis Mohideen, President Trump, Prevail Therapeutics, protein degradation, Regeneron Pharmaceuticals, Retrophin, Robert Forrester, Roche, Sanofi, Singular Bio, small cell lung cancer, SpringWorks Therapeutics, startups, Stoke Therapeutics, SVB Leerink, Ultragenyx Pharmaceutical, uniQure, Unity Biotechnology, Unum Therapeutics, vaccines, Verastem, Voyager Therapeutics | Comments Off

Auth0 Gets “Unicorn” Status as It Raises $103M for Security Tools

Auth0, a Bellevue, WA-based developer of user identification and login tools for software makers and large businesses, announced Monday it has raised $103 million in new financing. Under the terms of the deal, investors valued Auth0 at more than $1 billion, putting it among the ranks of tech startup “unicorns.” Sapphire Ventures, based in Silicon […]

Posted in National blog main, San Francisco blog main, Seattle, Seattle blog main, Seattle top stories | Tagged anders ranum, Auth0, Bessemer Venture Partners, Cisco Systems, Convoy, Cybersecurity, Data breaches, data hacks, Duo Security, hacks, IBM, IPOs, K9 Ventures, Lyft, Meritech Capital, OfferUp, Okta, Outreach, Pinterest, Software, Tech, Trinity Ventures, Unicorns, wall street, World Innovation Lab | Comments Off← Older posts

Tag Archives: IPOs

Archives

Meta